SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 58.00+3.6%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (388)4/7/2013 10:45:40 PM
From: ghmm  Read Replies (2) of 507
 
I remember them talking about this at their R&D Day Event last year. Its certainly early but I thought it seems like an intriguing compound with a good deal of potential. I think efficacy is not the major barrier but rather tolerability will be the key. If this drug could reduce the need to have to hospitalize patients to treat them it could certainly but a more viable treatment option for melanoma patients then those getting IL-2 therapy in a few research centers now.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News